Fundamental Expertise

The last decades have been shaped by the rise of genetics. Personalized medicine and genomic profiling are today's headliners. Gene therapies are aimed at the root of a disease instead of pure symptom treatment. Experts are forecasting a skyrocket take-off of gene therapeutics in the near future. Biovisory has exhaustive expert knowledge in in vivo and ex vivo gene therapy approaches, markets and players.

Project example(s):

• Global C&G strategy for a top pharma company: Biovisory support comprised all in vivo and ex vivo gene therapeutic technologies.

• Several European biotech companies (all ATMPs, including RNA therapies): Biovisory supported the transition from preclinical to clinical stage by e.g. the establishment of a Project Management Office (PMO), clinical development planning and regulatory strategy (CMC, preclinical and clinical).